Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01456416 · ClinicalTrials.gov registry record
Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities
A clinical trial of Relapsing Remitting Multiple Sclerosis, sponsored by University of Southern California.
- Completed
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT01456416: Completed study of Relapsing Remitting Multiple Sclerosis, sponsored by University of Southern California.
NCT01456416 is a study of Relapsing Remitting Multiple Sclerosis that has completed, run by University of Southern California. The registered enrollment target is 10 participants, below the 202-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01456416, a study of Relapsing Remitting Multiple Sclerosis, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The incidence of autoimmune conditions is at least 2-3 times higher in Multiple Sclerosis population than in general population. These MS patients category response unfavorably to the Interferon. The investigators suggest that autoimmune co morbidity can serve as a biological marker predicting good response to GA.
Primary Outcome
The primary objective is to determine whether daily GA injections do not aggravate comorbid autoimmune conditions.
Conditions Studied
Study Locations (1)
California
- USC MS Comprehensive Care Center & Research Group - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-04 |
What the finished NCT01456416 record still lists
NCT01456416 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 202-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Relapsing Remitting Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT01456416 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01456416 about?
NCT01456416 is a clinical study titled "Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities". The incidence of autoimmune conditions is at least 2-3 times higher in Multiple Sclerosis population than in general population. These MS patients category response unfavorably to the Interferon. The investigators suggest that autoimmune co morbidity can serve as a biological marker predicting good ...
What is the current status of trial NCT01456416?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2011-09. Estimated completion is 2013-04.
What conditions does trial NCT01456416 study?
This clinical trial studies the following conditions: Relapsing Remitting Multiple Sclerosis.
Who is sponsoring clinical trial NCT01456416?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01456416 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Remitting Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01456416's enrollment target sits among peer trials
10 26th of 25 the lowest of 25 other Relapsing Remitting Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsing Remitting Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
RECRUITING
-
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
RECRUITING
-
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
RECRUITING · NA
-
Functional Outcomes From Diets in Multiple Sclerosis
RECRUITING · NA
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
RECRUITING · Phase 3
-
Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia